Selecting the right lead immune cell candidates is a pivotal step in achieving successful outcomes in both in vivo studies and clinical trials. Our Validation service takes the guesswork out of your decision-making and fast-tracks the development of your next breakthrough therapy.

We generate pre-clinical data that directly correlates with in vivo responses, allowing you to confidently select the most promising immunotherapy constructs that you have developed, before investing time and resources into costly in vivo studies and clinical trials. This means you can cherry-pick your lead assets that have the greatest likelihood of in vivo success.

We support a wide range of cell-based immunotherapies, including TCR-T, CAR-T, NK cells, and more. Whether you are developing therapies for solid tumors or autoimmune diseases, we provide critical insights to streamline the development of your immunotherapies and accelerate your path to success.